secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001493152-24-014067
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix Q4 2023 revenue $1.2M record; CMS reimbursement still not approved
-------------------------------------------------------------------------------

- Q4 2023 revenue of $1.2M (record quarter); loss from operations of $702K.
- Cash of $3.3M, inventory $2.7M; raised $4.2M net in Q3 2023.
- CMS reimbursement for PainShield still not approved; efforts continue.
- University of Michigan to initiate UroShield RCT (pilot 30, full study 300+).
- Selected engineering partner for next-gen product development expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315224014067/0001493152-24-014067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315224014067/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer